Mutations in porin LamB contribute to ceftazidime-avibactam resistance in KPC-producing Klebsiella pneumoniae

被引:26
|
作者
Guo, Yingyi [1 ]
Liu, Ningjing [1 ]
Lin, Zhiwei [2 ]
Ba, Xiaoliang [3 ]
Zhuo, Chuyue [1 ]
Li, Feifeng [1 ]
Wang, Jiong [1 ]
Li, Yitan [2 ]
Yao, Likang [1 ]
Liu, Baomo [1 ]
Xiao, Shunian [1 ]
Jiang, Ying [1 ]
Zhuo, Chao [1 ]
机构
[1] Guangzhou Med Univ, Affiliated Hosp 1, Guangzhou Inst Resp Hlth, Guangzhou, Peoples R China
[2] Peoples Hosp Yangjiang, Lab Resp Dis, Yangjiang, Guangdong, Peoples R China
[3] Univ Cambridge, Dept Vet Med, Cambridge, England
基金
中国国家自然科学基金;
关键词
Ceftazidime-avibactam; KPC; LamB; PBP3; expression level of bla (KPC); IN-VITRO ACTIVITY; ESCHERICHIA-COLI; MOLECULAR EPIDEMIOLOGY; ENTEROBACTERIACEAE; ACID;
D O I
10.1080/22221751.2021.1984182
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Ceftazidime-avibactam (CAZ-AVI) shows promising activity against carbapenem-resistant Klebsiella pneumoniae (CRKP), however, CAZ-AVI resistance have emerged recently. Mutations in KPCs, porins OmpK35 and/or OmpK36, and PBPs are known to contribute to the resistance to CAZ-AVI in CRKP. To identify novel CAZ-AVI resistance mechanism, we generated 10 CAZ-AVI-resistant strains from 14 CAZ-AVI susceptible KPC-producing K. pneumoniae (KPC-Kp) strains through in vitro multipassage resistance selection using low concentrations of CAZ-AVI. Comparative genomic analysis for the original and derived mutants identified CAZ-AVI resistance-associated mutations in KPCs, PBP3 (encoded by ftsI), and LamB, an outer membrane maltoporin. CAZ-AVI susceptible KPC-Kp strains became resistant when complemented with mutated bla (KPC) genes. Complementation experiments also showed that a plasmid borne copy of wild-type lamB or ftsI gene reduced the MIC value of CAZ-AVI in the induced resistant strains. In addition, bla (KPC) expression level increased in four of the six CAZ-AVI-resistant strains without KPC mutations, indicating a probable association between increased bla (KPC) expression and increased resistance in these strains. In conclusion, we here identified a novel mechanism of CAZ-AVI resistance associated with mutations in porin LamB in KPC-Kp.
引用
收藏
页码:2042 / 2051
页数:10
相关论文
共 50 条
  • [31] First Report of Ceftazidime-Avibactam Resistance in a KPC-3-Expressing Klebsiella pneumoniae Isolate
    Humphries, Romney M.
    Yang, Shangxin
    Hemarajata, Peera
    Ward, Kevin W.
    Hindler, Janet A.
    Miller, Shelley A.
    Gregson, Aric
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2015, 59 (10) : 6605 - 6607
  • [32] Emergence of ceftazidime/avibactam resistance in KPC-3-producing Klebsiella pneumoniae in vivo
    Goettig, Stephan
    Frank, Denia
    Mungo, Eleonora
    Nolte, Anika
    Hogardt, Michael
    Besier, Silke
    Wichelhaus, Thomas A.
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2019, 74 (11) : 3211 - 3216
  • [33] Synergistic effects of ceftazidime/avibactam combined with meropenem in a murine model of infection with KPC-producing Klebsiella pneumoniae
    Zheng, Mei
    Li, Fu-Hao
    Liu, Juan
    Li, Wen-Jie
    Yin, Ruo-Xi
    Cai, Da-Tong
    Andrey, Diego O.
    Zheng, Si-Lin
    Gales, Ana C.
    Zhang, Wan-Jiang
    Sun, Jian
    Liao, Xiao-Ping
    Yu, Yang
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2024, 79 (05) : 1069 - 1080
  • [34] In Vitro Activity of Ceftazidime/Avibactam Alone and in Combination With Fosfomycin and Carbapenems Against KPC-producing Klebsiella Pneumoniae
    Romanelli, Federica
    De Robertis, Annalisa
    Carone, Gianluca
    Dalfino, Lidia
    Stufano, Monica
    Del Prete, Raffaele
    Mosca, Adriana
    NEW MICROBIOLOGICA, 2020, 43 (03): : 136 - 138
  • [35] Ceftazidime-avibactam in the treatment of infections caused by KPC-producing Klebsiella pneumoniae: factors associated with clinical efficacy in a single-center cohort
    Jose Caston, Juan
    Gallo, Marina
    Garcia, Manuel
    Cano, Angela
    Escribano, Antonio
    Machuca, Isabel
    Gracia-Aufinger, Irene
    Guzman-Puche, Julia
    Perez-Nadales, Elena
    Recio, M.
    Munoz, Monserrat
    Martinez-Martinez, Luis
    Torre-Cisneros, Julian
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2020, 56 (03)
  • [36] Bloodstream infection caused by KPC-producing Klebsiella pneumoniae resistant to ceftazidime/avibactam: epidemiology and genomic characterization
    Gaibani, P.
    Re, M. C.
    Campoli, C.
    Viale, P. L.
    Ambretti, S.
    CLINICAL MICROBIOLOGY AND INFECTION, 2020, 26 (04) : 516.e1 - 516.e4
  • [37] Epidemiology of resistance of carbapenemase-producing Klebsiella pneumoniae to ceftazidime-avibactam in a Chinese hospital
    Chen, D.
    Xiao, L.
    Hong, D.
    Zhao, Y.
    Hu, X.
    Shi, S.
    Chen, F.
    JOURNAL OF APPLIED MICROBIOLOGY, 2022, 132 (01) : 237 - 243
  • [38] Colonization by ceftazidime/avibactam-resistant KPC-producing Klebsiella pneumoniae following therapy in critically ill patients
    Gaibani, Paolo
    Bovo, Federica
    Bussini, Linda
    Bartoletti, Michele
    Lazzarotto, Tiziana
    Viale, Pierluigi
    Pea, Federico
    Ambretti, Simone
    CLINICAL MICROBIOLOGY AND INFECTION, 2023, 29 (05) : 654.e1 - 654.e4
  • [39] Emergence of ceftazidime/avibactam resistance in KPC-8-producing Klebsiella pneumoniae in South America
    Garcia, J.
    Nastro, M.
    Cejas, D.
    Santana, G.
    Mancino, M. B.
    Hidalgo, M.
    Maccallini, G.
    Vay, C.
    Radice, M.
    Dabos, L.
    Famiglietti, A.
    Rodriguez, H.
    CLINICAL MICROBIOLOGY AND INFECTION, 2020, 26 (09) : 1264 - 1265
  • [40] Prevalence and mortality of ceftazidime/avibactam-resistant KPC-producing Klebsiella pneumoniae bloodstream infections (2018–2022)
    Matteo Boattini
    Gabriele Bianco
    Paulo Bastos
    Sara Comini
    Silvia Corcione
    André Almeida
    Cristina Costa
    Francesco Giuseppe De Rosa
    Rossana Cavallo
    European Journal of Clinical Microbiology & Infectious Diseases, 2024, 43 : 155 - 166